Inactive Instrument

Epigenomics AG Share Price Deutsche Boerse AG

Equities

DE000A1K0516

Biotechnology & Medical Research

End-of-day quote Deutsche Boerse AG
- EUR - Intraday chart for Epigenomics AG

Financials

Sales 2024 * - Sales 2025 * - Capitalization 1.44M 1.55M 124M
Net income 2024 * - 0 0 Net income 2025 * - 0 0 EV / Sales 2024 * -
Net cash position 2024 * 2.48M 2.67M 213M Net cash position 2025 * 1.39M 1.49M 119M EV / Sales 2025 * -
P/E ratio 2024 *
-1.84 x
P/E ratio 2025 *
-2.87 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.77%
More Fundamentals * Assessed data
Managers TitleAgeSince
Investor Relations Contact - -
Human Resources Officer - -
Members of the board TitleAgeSince
Chairman 56 24/05/16
Director/Board Member 54 02-04
Director/Board Member 53 31/05/20
More insiders
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Calendar
More about the company